Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Schreuder, A.; de Lint, K.; Gois, M. M.; Kampen, R. A.; San Martin Alonso, M.; Nootenboom, I.; Garzero, V.; Wolthuis, R. M. F.; Noordermeer, S. M.
Show abstract
With the recent rise in CRISPR/Cas9-mediated genome-wide synthetic lethality screens, many new synthetic lethal targets have been identified for diseases with underlying genetic causes such as tumours with BRCA1 mutations. Such screens often use full deficiency of a protein to identify novel vulnerabilities. However, patient-derived mutations not only result in loss of the protein but often also concern missense mutations with hypomorphic phenotypes. Here we study the genetic vulnerabilities of two previously described hypomorphic BRCA1 missense mutations and compare these to a BRCA1-depleted setting to study whether this affects screening for synthetic lethal interactions. Our research showed that BRCA1I26A mutated cells have very similar vulnerabilities to BRCA1 wildtype cells, confirming its low tumorigenic effect. In contrast, the BRCA1R1699Q mutation induced a more similar phenotype to BRCA1-deficient cells. For this mutation, we also unveiled a unique vulnerability to the loss of NDE1. Specifically in BRCA1R1699Q mutated cells, and not BRCA1-proficient or -deficient cells, NDE1 loss leads to increased genomic instability. Altogether our findings highlight the importance to differentiate between patient-derived mutations when assessing novel treatment targets.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Phosphorylation Status Of MUS81 Is A Modifier Of Olaparib Sensitivity In BRCA2-Deficient Cells 97%
- Recovery of protein synthesis to measure transcription-coupled DNA repair in living cells and tissues 96%
- Separation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1 95%
Similar papers in this journal
- DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene 95%
- Inhibition of tryptophan-2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells 94%
- The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities. 93%
Similar papers in this journal
- Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells 95%
- A large-scale cancer-specific protein-DNA interaction network 93%
- A Novel Role for CSA in the Regulation of Nuclear Envelope Integrity: Uncovering a Non-Canonical Function 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.